Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells

Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells

Immune check point inhibitors targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1) have shown clinical success in treatment of human malignancies. Triple negative breast cancer (TNBC), which is primarily characterized by high heterogeneity and presence of tumor infiltrating lympho...

Full description

Bibliographic Details
Main Authors: Nishant Mohan, Salman Hosain, Jun Zhao, Yi Shen, Xiao Luo, Jiangsong Jiang, Yukinori Endo, Wen Jin Wu
Format: Article
Language:English
Published: Taylor & Francis Group 2019-09-01
Series:OncoImmunology
Subjects:
atezolizumab
immune checkpoint inhibitors
triple negative breast cancer (trbc)
pd-l1
focal adhesion kinase (fak)
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1624128

Internet

http://dx.doi.org/10.1080/2162402X.2019.1624128

Similar Items